Publicacions en què col·labora amb JOSÉ HERNÁNDEZ QUERO (30)

2022

  1. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Empirical treatment with doxycycline of fever of intermediate duration

    European Journal of Clinical Microbiology and Infectious Diseases

  3. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

  4. Hemophagocytic lymphohistiocytosis associated with Leishmania: A hidden passenger in endemic areas

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 4, pp. 188-191

2020

  1. Imported babesiosis caused by Babesia microti—A case report

    Ticks and Tick-borne Diseases

2019

  1. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status

    Cells, Vol. 7, Núm. 11

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Nebulized medication is not associated with nosocomial infections. A pilot study

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 154-156

  3. Rational application of adenosine deaminase activity in cerebrospinal fluid for the diagnosis of tuberculous meningitis

    Infection, Vol. 43, Núm. 5, pp. 531-535

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Letter: Accuracy of liver stiffness measurement - A comparison of two different FibroScan devices

    Alimentary Pharmacology and Therapeutics

  3. Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodes

    AIDS, Vol. 28, Núm. 12, pp. 1835-1837

2009

  1. Bacteriemia persistente por Staphylococcus aureus resistente a meticilina. El resultado de un tratamiento inadecuado

    Enfermedades Infecciosas y Microbiologia Clinica

  2. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230